Studies related to TMAO and Pyrroloquinoline quinone

Dietary Pyrroloquinoline Quinone (PQQ) Alters Indicators Of Inflammation And Mitochondrial-related Metabolism In Human Subjects

Effect Decrease
Trial Design Non-randomized controlled trial
Trial Length 2-4 Weeks
Number of Subjects 10
Sex Both Genders
Age Range 18-29
Body Types Average
Notes for this study:
In a preliminary study using PQQ at 0.075mg/kg for one week (doubled during week two, and then doubled again to 0.3mg/kg for the final week) in otherwise healthy humans noted a significant reduction in C-reactive protein (45%) and a decrease in IL-6 which paralleled C-RP, but the reduction in lipid peroxidation was very minor (0.2%) and other biomarkers of oxidation were not affected.

Urinary biomarkers suggested that mitochondrial efficiency was influenced in a beneficial manner as urinary fumarate, pyruvic acid, and lactate were all reduced; urinary amino acids were also reduced (suggesting retention of nitrogen) and a decrease in some urinary amines suggested increased beta-oxidation (a measure of fat oxidation).